Analysts think ARTV stock price could increase by 825%
Jun 14, 2025, 11:25 AM
2.77%
What does ARTV do
Artiva Biotherapeutics, based in San Diego, focuses on NK cell-based therapies for autoimmune diseases and cancers, with its lead candidate AlloNK in Phase I/Ib trials. The company went public on July 19, 2024.
7 analysts think ARTV stock price will increase by 824.94%. The current median analyst target is $18.36 compared to a current stock price of $1.99. The lowest analysts target is $10.10 and the highest analyst target is $21.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
